These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

179 related articles for article (PubMed ID: 16673608)

  • 1. Zometa in the treatment of diseminated prostate cancer.
    Djokic M
    Acta Chir Iugosl; 2005; 52(4):119-21. PubMed ID: 16673608
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Zoledronic acid(ZOMETA): a significant improvement in the bone metastases.
    Nagy Z
    Pathol Oncol Res; 2005; 11(3):186-7. PubMed ID: 16299941
    [No Abstract]   [Full Text] [Related]  

  • 3. Complete clinical and biological response to zoledronic acid in castrate-resistant prostate cancer metastatic to bone.
    Pouessel D; Culine S
    Anticancer Drugs; 2012 Jan; 23(1):141-2. PubMed ID: 21934600
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Zoledronic acid (Zometa): bisphosphonate for prostate cancer/bone metastases.
    Gaines KK
    Urol Nurs; 2002 Dec; 22(6):398-400. PubMed ID: 12593231
    [No Abstract]   [Full Text] [Related]  

  • 5. Words of Wisdom. Re: Randomized Controlled Trial of Early Zoledronic Acid in Men with Castration-sensitive Prostate Cancer and Bone Metastases: Results of CALGB 90202 (Alliance).
    Kimura T; Egawa S
    Eur Urol; 2016 Apr; 69(4):754-5. PubMed ID: 26972498
    [No Abstract]   [Full Text] [Related]  

  • 6. Rationale for zoledronic acid therapy in men with hormone-sensitive prostate cancer with or without bone metastasis.
    Saad F; McKiernan J; Eastham J
    Urol Oncol; 2006; 24(1):4-12. PubMed ID: 16414486
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Zoledronic acid and osseous pathologies in the course of neoplasia. Part II].
    Caffo O
    Tumori; 2005; 91(6):suppl 23-7. PubMed ID: 16457163
    [No Abstract]   [Full Text] [Related]  

  • 8. Bone disease in prostate cancer.
    Nagrial A; Horvath L
    Asia Pac J Clin Oncol; 2010 Mar; 6(1):3-4. PubMed ID: 20398032
    [No Abstract]   [Full Text] [Related]  

  • 9. Clinical efficacy and safety of zoledronic acid in prostate and breast cancer.
    Doggrell SA
    Expert Rev Anticancer Ther; 2009 Sep; 9(9):1211-8. PubMed ID: 19761424
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Combined use of zoledronic acid and 153Sm-EDTMP in hormone-refractory prostate cancer patients with bone metastases.
    Lam MG; Dahmane A; Stevens WH; van Rijk PP; de Klerk JM; Zonnenberg BA
    Eur J Nucl Med Mol Imaging; 2008 Apr; 35(4):756-65. PubMed ID: 18157530
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [The effect of bisphosphonates on bone metastasis of hormone-refractory prostate cancer].
    Tanaka T; Kawashima H; Kuratsukuri K; Sugimura K; Nakatani T
    Hinyokika Kiyo; 2006 Jun; 52(6):491-4. PubMed ID: 16848364
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Zoledronic acid treatment for cancerous bone metastases: a phase IV study in Taiwan.
    Chiang PH; Wang HC; Lai YL; Chen SC; Yen-Hwa W; Kok CK; Ou YC; Huang JS; Huang TC; Chao TY
    J Cancer Res Ther; 2013; 9(4):653-9. PubMed ID: 24518712
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Zoledronic acid is effective in the treatment of prostate cancer patients with bone metastases.
    Maung K
    Clin Prostate Cancer; 2002 Jun; 1(1):12-3. PubMed ID: 15046707
    [No Abstract]   [Full Text] [Related]  

  • 14. Metastatic Prostate Cancer and the Bone: Significance and Therapeutic Options.
    Gartrell BA; Coleman R; Efstathiou E; Fizazi K; Logothetis CJ; Smith MR; Sonpavde G; Sartor O; Saad F
    Eur Urol; 2015 Nov; 68(5):850-8. PubMed ID: 26153564
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effect of zoledronic acid on metastatic hormone-refractory prostate cancer resistant to taxane, estramustine, carboplatin, and dexamethasone.
    Kikuno N; Urakami S; Nakamura S; Shiina H; Igawa M
    Int J Urol; 2007 Jan; 14(1):82-4. PubMed ID: 17199867
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Explaining objective responses to zoledronic acid.
    Sorscher SM
    Anticancer Drugs; 2012 Nov; 23(10):1121. PubMed ID: 23023113
    [No Abstract]   [Full Text] [Related]  

  • 17. Is time to first skeletal-related event the best primary end point in the assessment of bisphosphonate efficacy in patients with castration-sensitive prostate cancer?
    Valcamonico F; Petrelli F; Ferrari L; Ferrari V; Grisanti S; Barni S; Berruti A
    J Clin Oncol; 2014 Nov; 32(32):3684-5. PubMed ID: 25225432
    [No Abstract]   [Full Text] [Related]  

  • 18. Optimising treatment of bone metastases by Aredia(TM) and Zometa(TM).
    Coleman RE
    Breast Cancer; 2000; 7(4):361-9. PubMed ID: 11114866
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Zoledronic acid in the treatment of prostate cancer].
    Conti G
    Minerva Urol Nefrol; 2005 Dec; 57(4):313-7. PubMed ID: 16247352
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Treatment of painful bone metastases in hormone-refractory prostate cancer with zoledronic acid and samarium-153-ethylenediaminetetramethylphosphonic acid combined.
    Lam MG; de Klerk JM; Zonnenberg BA
    J Palliat Med; 2009 Jul; 12(7):649-51. PubMed ID: 19594354
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.